<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471638</url>
  </required_header>
  <id_info>
    <org_study_id>STP 115</org_study_id>
    <nct_id>NCT02471638</nct_id>
  </id_info>
  <brief_title>DETOUR I Clinical Study</brief_title>
  <official_title>PQ Bypass Systems for Femoropopliteal Bypass II (PQB 4 FP II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PQ Bypass, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PQ Bypass, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and performance of the PQ Bypass System to access, deliver guidewires&#xD;
      and implant stent grafts for a percutaneous fem-pop bypass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single-arm, multi-center, international, non-randomized, pre-market, safety and&#xD;
      effectiveness clinical investigation evaluating the PQ Bypass Systems to access, deliver&#xD;
      guidewires and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Performance Endpoint (Rate of primary patency)</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of primary patency. Primary patency defined as: no evidence of clinically significant stenosis (≥50%) within the stent graft or immediately above or below the treated arterial segment based on duplex ultrasound (systolic velocity ratio of &gt;2.5).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Single arm study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PQ Bypass System for Femoropopliteal Bypass</intervention_name>
    <description>To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Rutherford Classification of 3-5&#xD;
&#xD;
          -  Patent iliac and femoral arteries/veins and access vessels, of sufficient size and&#xD;
             morphology (including tortuosity), to allow endovascular access with 8 Fr. introducer&#xD;
             sheath&#xD;
&#xD;
          -  Femoro-popliteal lesions ≥10 cm in length considered to be:&#xD;
&#xD;
               -  Chronic total occlusion (100% stenosis)&#xD;
&#xD;
               -  Diffuse stenosis (&gt;50% stenosis) with moderate to heavy calcification&#xD;
&#xD;
               -  In-stent restenosis (&gt;50% stenosis)&#xD;
&#xD;
          -  Proximal and distal target vessels are 5.4-7.0 mm in diameter&#xD;
&#xD;
          -  Orifice and proximal 1 cm of SFA is patent&#xD;
&#xD;
          -  Patent popliteal artery 3 cm proximal to tibial plateau&#xD;
&#xD;
          -  At least 1 patent tibial artery to the foot&#xD;
&#xD;
          -  Patent femoral vein ≥ 10 mm in diameter or duplicate femoral vein&#xD;
&#xD;
          -  Subject has &gt; one year life expectancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bypass length required &gt; 30 cm&#xD;
&#xD;
          -  History of deep vein thrombosis&#xD;
&#xD;
          -  Has a known hypersensitivities, allergies or contraindications to: nitinol, PTFE;&#xD;
             aspirin, heparin, antiplatelet, anticoagulant or thrombolytic therapy; or&#xD;
             anticoagulation or contrast media that is not amenable to pre-treatment;&#xD;
&#xD;
          -  Has a known history of intracranial bleeding or aneurysm, myocardial infarction or&#xD;
             stroke within the last 12 months&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Untreated flow-limiting aortoiliac occlusive disease&#xD;
&#xD;
          -  Has renal failure (eGFR &lt; 30mL/min)&#xD;
&#xD;
          -  Major distal amputation (above the transmetatarsal) in the study or non-study limb&#xD;
&#xD;
          -  Patient has had a revascularization procedure on the target limb within 30 days&#xD;
&#xD;
          -  Patient has a planned amputation of the target limb&#xD;
&#xD;
          -  Previous bypass surgery on the target limb&#xD;
&#xD;
          -  Patient is participating in another clinical study for which follow-up is currently on&#xD;
             going.&#xD;
&#xD;
          -  Patient has a condition that in the view of the investigator precludes participation&#xD;
             in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig Medical Centre</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stradins University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Service</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gdansk Medical University</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Haematology Medicine Indira Gandhi</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>New Zealand</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 5, 2020</submitted>
    <returned>December 2, 2020</returned>
    <submitted>December 2, 2020</submitted>
    <returned>December 31, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

